메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 29, Issue 29, 2011, Pages 3944-3945
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation
Author keywords

[No Author keywords available]
Indexed keywords

BUSULFAN; HYDROXYUREA; IMATINIB; INTERFERON;
EID: 80053977453     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.6962     Document Type: Letter
Times cited : (51)
References (7)
  • 1
    • 0021336851 scopus 로고
    • Prognostic discrimination in "goodrisk" chronic granulocytic leukemia
    • Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "goodrisk" chronic granulocytic leukemia. Blood 63:789-799, 1984
    • (1984) Blood , vol.63 , pp. 789-799
    • Sokal, J.E.1    Cox, E.B.2    Baccarani, M.3
  • 2
    • 0029041749 scopus 로고
    • UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response - The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia
    • Allan NC, Richards SM, Shepherd PC: UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response - The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345:1392-1397, 1995
    • (1995) Lancet , vol.345 , pp. 1392-1397
    • Allan, N.C.1    Richards, S.M.2    Shepherd, P.C.3
  • 3
    • 33845444046 scopus 로고    scopus 로고
    • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    • Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
    • (2006) N Engl J Med , vol.355 , pp. 2408-2417
    • Druker, B.J.1    Guilhot, F.2    O'Brien, S.G.3
  • 4
    • 49149111543 scopus 로고    scopus 로고
    • Imatinib for newly diagnosed patients with chronic myeloid leukaemia: Incidence of sustained responses in an intention-to-treat analysis
    • de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukaemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 3358-3363
    • De Lavallade, H.1    Apperley, J.F.2    Khorashad, J.S.3
  • 5
    • 0042528659 scopus 로고    scopus 로고
    • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa
    • Marin D, Marktel S, Bua M, et al: Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 17:1448-1453, 2003
    • (2003) Leukemia , vol.17 , pp. 1448-1453
    • Marin, D.1    Marktel, S.2    Bua, M.3
  • 6
    • 76549114789 scopus 로고    scopus 로고
    • Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    • Milojkovic D, Nicholson E, Apperley JF, et al: Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95:224-231, 2010
    • (2010) Haematologica , vol.95 , pp. 224-231
    • Milojkovic, D.1    Nicholson, E.2    Apperley, J.F.3
  • 7
    • 79960685618 scopus 로고    scopus 로고
    • Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score
    • Hasford J, Baccarani M, Hoffmann V, et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 118:686-692, 2011
    • (2011) Blood , vol.118 , pp. 686-692
    • Hasford, J.1    Baccarani, M.2    Hoffmann, V.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.